US Patent 11028161 Treating refractory migraine
All edits
Edits on 12 Dec, 2023
Golden AI
Edits made to:
Article (+454 characters)
Article
Patent abstract
Disclosed herein are methods of treating or reducing incidence of migraine and/or at least one secondary symptom associated with refractory migraine in a subject having refractory migraine comprising administering to the subject a monoclonal antibody that modulates the CGRP pathway. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.
Edits on 18 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 3 Apr, 2023
Golden AI
Infobox
Is a
Patent Jurisdiction
Patent Number
110281610
Date of Patent
June 8, 2021
0Patent Application Number
170767720
Date Filed
October 21, 2020
0Official Website
Patent Citations
Patent Citations Received
Patent Primary Examiner
Edits on 1 Apr, 2023
Golden AI
Infobox
Edits on 22 Mar, 2023
Golden AI
Edits on 18 Jan, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 26 Sep, 2022
Golden AI
Edits on 22 Sep, 2022
Golden AI
Infobox
Is a
Patent Jurisdiction
Patent Number
110281610
Date of Patent
June 8, 2021
0Patent Application Number
170767720
Date Filed
October 21, 2020
0Official Website
Patent Citations
Patent Primary Examiner
Edits on 6 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 12 Feb, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 11028161 Treating refractory migraine
Infobox
Is a
Patent jurisdiction
Patent number
11028161
Date of patent
June 8, 2021
Patent application number
17076772
Date Filed
October 21, 2020
Patent citations
Patent primary examiner
Find more entities like US Patent 11028161 Treating refractory migraine
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
